Legend Biotech Corporation (LEGN)
- Previous Close
45.52 - Open
45.65 - Bid 43.15 x 200
- Ask 43.26 x 200
- Day's Range
42.96 - 45.70 - 52 Week Range
42.08 - 77.32 - Volume
887,591 - Avg. Volume
1,002,052 - Market Cap (intraday)
7.866B - Beta (5Y Monthly) 0.12
- PE Ratio (TTM)
-- - EPS (TTM)
-2.94 - Earnings Date May 13, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
86.52
Legend Biotech Corporation, a clinical-stage biopharmaceutical company, through its subsidiaries, engages in the discovery, development, manufacturing, and commercialization of novel cell therapies for oncology and other indications in the United States, China, and internationally. Its lead product candidate, LCAR- B38M, is a chimeric antigen receptor for the treatment of multiple myeloma (MM). The company also has a portfolio of earlier-stage autologous CAR-T product candidates targeting various cancers, including Non-Hodgkins Lymphoma, acute lymphoblastic leukemia, gastric cancer, esophageal cancer, pancreatic cancer, colorectal cancer, hepatocellular carcinoma, small cell lung cancer, and non-small cell lung cancer. It has collaboration and license agreement with Janssen Biotech, Inc. for the development and commercialization of ciltacabtagene autoleucel. The company was founded in 2014 and is based in Somerset, New Jersey. Legend Biotech Corporation is a subsidiary of Genscript Biotech Corporation.
www.legendbiotech.comRecent News: LEGN
Performance Overview: LEGN
Trailing total returns as of 5/13/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: LEGN
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: LEGN
Valuation Measures
Market Cap
7.87B
Enterprise Value
6.89B
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
26.70
Price/Book (mrq)
6.29
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
-181.75%
Return on Assets (ttm)
-17.38%
Return on Equity (ttm)
-51.94%
Revenue (ttm)
285.14M
Net Income Avi to Common (ttm)
-518.25M
Diluted EPS (ttm)
-2.94
Balance Sheet and Cash Flow
Total Cash (mrq)
1.31B
Total Debt/Equity (mrq)
26.26%
Levered Free Cash Flow (ttm)
-441.19M
Research Analysis: LEGN
Company Insights: LEGN
LEGN does not have Company Insights